Evidence map›Paper›PMID 30872156›Full record

ReviewJournal of the American Academy of Dermatology2019

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.

Ali Alikhan, Christopher Sayed, Afsaneh Alavi, Raed Alhusayen, Alain Brassard, Craig Burkhart, Karen Crowell, Daniel B Eisen, Alice B Gottlieb, Iltefat Hamzavi and 10 more

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the American Academy of Dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05580029 (Open Label Prospective Trial of Fractional Ablative CO 2 Resurfacing With Laser- Facilitated Steroid Delivery in Patients With Mild to Moderate Hidradenitis Suppurativa.), which is not on this map. Cited by 146 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05580029 early_phase1unknown statusnot on this mapstarted 2022, after this paper: background citation

Open Label Prospective Trial of Fractional Ablative CO 2 Resurfacing With Laser- Facilitated Steroid Delivery in Patients With Mild to Moderate Hidradenitis Suppurativa.

TypeinterventionalSponsorUniversity of Southern CaliforniaRan2022 to 2023Enrolled10ConditionsScar, Hidradenitis SuppurativaArmsTriamcinolone Topical, Fractional Ablative CO2 Therapy, EMLA 5% cream
3 · Its place in the literature

Who cites it

146 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Pooled it
  2. Pooled it
  3. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Guideline
  4. Australasian hidradenitis suppurativa management guidelines.The Australasian journal of dermatology · 2025
    Guideline
  5. Guideline
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Article
  12. High- and Ultra-High-Frequency Ultrasound Identifies a Subclinical Link Between Suppurative Comedonal Nevus and Hidradenitis Suppurativa.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Ali AlikhanSutter Health, Sacramento, California.
Christopher SayedDepartment of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: christopher_sayed@med.unc.edu.
Afsaneh AlaviDepartment of Medicine, Division of Dermatology, University of Toronto, Toronto, Ontario, Canada.
Raed AlhusayenDepartment of Medicine, Division of Dermatology, University of Toronto, Toronto, Ontario, Canada.
Alain BrassardDepartment of Dermatology, University of California at Davis, Sacramento, California.
Craig BurkhartDepartment of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Karen CrowellHealth Sciences Library, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Daniel B EisenDepartment of Dermatology, University of California at Davis, Sacramento, California.
Alice B GottliebDepartment of Dermatology, Icahn School of Medicine at Mt Sinai Hospital, New York, New York.
Iltefat HamzaviDepartment of Dermatology, Henry Ford Hospital, Detroit, Michigan.
Paul G HazenAssociates in Dermatology, Westlake, Ohio.
Tara JaleelDepartment of Dermatology, Duke University School of Medicine, Durham, North Carolina.
Alexa B KimballDepartment of Dermatology, Harvard Medical School, Boston, Massachusetts.
Joslyn KirbyDepartment of Dermatology, Penn State Hershey Medical Center, Hershey, Pennsylvania.
Michelle A LowesLaboratory for Investigative Dermatology, New York, New York.
Robert MichelettiDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Angela MillerDepartment of Dermatology, Henry Ford Hospital, Detroit, Michigan.
Haley B NaikDepartment of Dermatology, University of California San Francisco, San Francisco, California.
Dennis OrgillDivision of Plastic Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
Yves PoulinCentre de Recherche Dermatologique du Quebec Metropolitain, Quebec City, Quebec, Canada.

Funding

Institutional Career Development Core SupplementKL2TR001870 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KANAYA, ALKA M., SARKAR, URMIMALA · 2016 to 2025
$19.7M
Microbial Shifts and Immune Dysregulation in Hidradenitis Suppurativa PathogenesisK23AR074531 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NAIK, HALEY · 2019 to 2023
$887k
NIAMS NIH HHS K23 AR074531
6 · The paper itself

Abstract

Hidradenitis suppurativa is a chronic inflammatory disorder affecting hair follicles, with profoundly negative impact on patient quality of life. Evidence informing ideal evaluation and management of patients with hidradenitis suppurativa is still sparse in many areas, but it has grown substantially in the last decade. Part I of this evidence-based guideline is presented to support health care practitioners as they select optimal management strategies, including diagnostic testing, comorbidity screening, and both complementary and procedural treatment options. Recommendations and evidence grading based on the evidence available at the time of the review are provided.

Indexed as

Practice Guidelines as TopicAnti-Bacterial AgentsBiological ProductsCanadaComplementary TherapiesDermatologic Surgical ProceduresDrug Therapy, CombinationEvidence-Based MedicineFemaleHidradenitis SuppurativaHumansImmunosuppressive AgentsMaleNorth AmericaPublishingRisk AssessmentAnti-Bacterial AgentsBiological ProductsImmunosuppressive Agentsacne inversaadalimumabbiomarkerscarbon dioxide laserclindamycincomorbiditiesertapenemfinasterideguidelineshidradenitis suppurativainfliximablaserlifestyle modificationmicrobiomeNd:YAGoral contraceptive pillsrifampinspironolactone

Identifiers

PMID30872156
PMCPMC9131894

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.